Research Analysts Offer Predictions for BioXcel Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for BioXcel Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.51) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.61) EPS.

Other analysts have also recently issued research reports about the stock. Bank of America reduced their target price on shares of BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. UBS Group reiterated a “neutral” rating and issued a $4.00 price objective (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st. Finally, Canaccord Genuity Group reduced their price objective on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $16.86.

BioXcel Therapeutics Stock Performance

BTAI stock opened at $2.59 on Wednesday. BioXcel Therapeutics has a one year low of $1.91 and a one year high of $29.56. The stock has a market capitalization of $79.20 million, a PE ratio of -0.42 and a beta of 0.40. The company has a fifty day moving average of $2.91 and a 200-day moving average of $3.18.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.22. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative return on equity of 890.63%. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.17 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in shares of BioXcel Therapeutics by 0.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 143,893 shares of the company’s stock worth $2,685,000 after purchasing an additional 611 shares in the last quarter. Legal & General Group Plc lifted its position in shares of BioXcel Therapeutics by 7.5% during the fourth quarter. Legal & General Group Plc now owns 9,678 shares of the company’s stock worth $208,000 after purchasing an additional 678 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in BioXcel Therapeutics by 5.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 14,747 shares of the company’s stock valued at $195,000 after acquiring an additional 794 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in BioXcel Therapeutics by 9.5% in the fourth quarter. JPMorgan Chase & Co. now owns 11,595 shares of the company’s stock valued at $249,000 after acquiring an additional 1,006 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in BioXcel Therapeutics by 205.2% in the first quarter. Tower Research Capital LLC TRC now owns 1,529 shares of the company’s stock valued at $29,000 after acquiring an additional 1,028 shares in the last quarter. 30.68% of the stock is owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.